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Ebola Virus
• Member of the filoviridae family of viruses, first discovered in 1976 in
the Ebola river (Zaire, now, Democratic Republic of Congo)
• Hemorrhagic fever and deadly disease caused by infection with one
of the Ebola virus strains (Human: Zaire, Sudan, Ivory Coast,
Bundibugyo; non-human primates: Reston)
• Animal-borne virus, with fruit bats as most likely reservoir
− Natural reservoir host not yet identified

• Transmission by direct contact (through broken skin or mucous
membranes) with blood or body fluids of infected individual or
contaminated objects, and infected fruit bats or primates

Ebola Virus Disease: Clinical Features
• Acute onset; typically 8 -10 days after exposure (range 2 – 21 days)
• Nonspecific early clinical signs and symptoms
− Initial


Fever, chills, myalgia, malaise, anorexia

− After 5 days, GI symptoms:


Nausea, vomiting, watery diarrhea, abdominal pain

− Hemorrhagic symptoms in 18% cases

• Symptoms progress to:
− Hemorrhagic disease
− Hypovolemic shock, multi-organ failure
− Death (case fatality rate >50%)
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2014 – 2016 Ebola Virus Outbreak
• First case in Guinea March 2014 and peaked in Aug–Oct ’14
− WHO declaration of Public Health Emergency on International
Concern (PHEIC) on August 8th

• Zaire ebolavirus species
• Cumulatively 28,000+ cases and 11,000+ deaths by January
2016
− > 10 times more cases during the current epidemic than in all previous
outbreaks combined
− Impacted: Guinea, Liberia, Sierra Leone


A few cases reported in Nigeria, Mali, Senegal, Spain, US, UK, and Italy

• WHO declares outbreak over on January 14th, 2016
− New cases have been detected in Sierra Leone since
http://who.int/mediacentre/news/releases/2016/eb
ola-zero-liberia/en/

Ebola Clinical Candidates During 2014 – 2016
Western African Outbreak

Taken from WHO Report on Ebola R&D Landscape of Official Candidates and Trials (October 2015)

Development History for Merck’s Ebola
Vaccine Candidate
•

Application of the rVSV technology and initial development of the candidate Ebola vaccine was
accomplished by Public Health Agency of Canada (PHAC)

•

PHAC licensed the filovirus vaccine technology to NewLink Genetics to further development and
initiate clinical development

•

The initial PHAC clinical lot was manufactured in 2013 by the German CMO and utilized in most
clinical trials
•
•

•
•

•

Towards the end of 2014, Merck and NewLink Genetics Corp. entered into an exclusive worldwide
license agreement
•

•

NewLink Genetics filed IND and started Phase I trials (3 sites) and oversaw the clinical development
Funding to support development and clinical lots completed by multiple partners
•
BARDA, DTRA, Wellcome Trust, NIH, NIAID and WHO
PHAC lot utilized to support Phase II/III in West Africa (Liberia, Guinea, Sierra Leone)
NewLink Genetics continued to work with IDT for additional clinical lots and process development

Merck assumed responsibility to research, develop, manufacture, and distribute the investigational Ebola vaccine
candidate (rVSV- ∆G-ZEBOV-GP) and other filovirus based vaccines based on rVSV technology

Merck, NewLink Genetics and a global network of partners are collaborating in unprecedented ways
with the singular focus on speeding the research, development and deployment of a well-tolerated
and effective Ebola vaccine

Composition of Merck’s Ebola Vaccine
Candidate (rVSV- ∆G-ZEBOV-GP)
Vector = live attenuated recombinant vesicular stomatitis
virus (rVSV)
− Antigen = Zaire Ebola virus (ZEBOV) glycoprotein (GP)



VSV G (envelope) GP replaced with Ebola-Zaire envelope GP
Eliminates VSV GP toxicity and changes host range

• rVSV-∆G-ZEBOV-GP is replication-competent, displaying ZEBOV GP in native
conformation on the surface of the VSV particle
•

Preclinical and clinical data suggest that a single dose of V920 is sufficient for inducing
rapid, protective responses
•

Consistent with utility in resource poor environments and in an outbreak situation
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WHO Guinea Ring Vaccination Trial: Interim
Analysis Efficacy Results
Lancet publication of Interim
Analysis on July 31st 2015
•

First evidence of efficacy in
human subjects for any Ebola
vaccine

•

No EVD cases in either
immediate or delayed arm from
Day 6 post dose onward

•

Study expanded into Sierra
Leone with all additional
subjects vaccinated upon
enrollment (no delayed arm)

•

Enrolling adolescents and
children > 6 years old

Merck’s Approach to Address Potential
Vaccine Needs and Vaccine Availability
• Move monovalent frozen product forward for licensure as efficiently as possible
− Complete clinical development to produce required safety database, demonstrate evidence of clinical
benefit, and manufacturing consistency
− Prepare commercial manufacturing facility and execute on manufacturing scale-up and PPQ activities

• Collaborate with current dose owners and stakeholders to align on best use of existing
doses of vaccine (~150 – 170K currently exist)
− Through expanded ring vaccination trials, new/expanded trials for at-risk US-based and ex-US populations,
trials in special populations etc.

• Ramp up Merck manufacturing capabilities (Pilot Plant) to produce additional doses that
could be deployed in the case of expanded or new outbreak (not commercial doses; only
for clinical trials or emergency use)
− Ethical obligation to ensure vaccine available in the event of another epidemic
− Merck now has successfully manufactured and stored ~120K doses and ~500K dose equivalents

• Kick off early development of thermostable product(s) to protect against key Filoviruses

Typical Timeline for Vaccine Development
10 to 20 Years

Standard timeline to develop a vaccine.

2014

2024+

Merck’s Vaccine Milestones and Accelerated
Timeline to Develop the Ebola Vaccine
Over 18,000 volunteers vaccinated to date

31 July 15

Phase III ring
vaccination trial
interim analysis
results
demonstrate
vaccine efficacy

2014

17 Aug 15

Initiation
of Merck Phase III
Safety and Lot
Consistency Study
(P012)
in US/EU/Canada

23 Aug 15

Siting
Decision and
Process
Development
Kicked-off
Internally

Sep 15

CAPEX
Scoping
Project
Initiated at
Manufacturing
Site

Nov 15

BARDA
Lots F/F
@ Merck

Jan/Feb 16
Manufacture
of DP Lots
for EMU
within Merck
Facility

Dec 15
Manufacture
of BDS Lots
for EMU at
Anticipated
Commercial
Scale

2016

2015

SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB
II/III

I

13 Oct 2014

Start of
Phase I trials
rVSV-ZEBOVGP

25 Jan
2015

Dose
selection
decision for
efficacy trials

2 Feb 2015
Initiation of
NIH-Liberia
PREVAIL
Phase II/III
study

III

23 Mar 2015

Initiation of
WHO
Phase III
study in Guinea

III

09 April 2015

Initiation
of CDC
STRIVE
Phase III trial
in Sierra Leone

22 Dec 2015

WHO agrees to
review an
Emergency Use
Assessment and
Listing
submission
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Process Development

13

Scope of Process Development
• Obtain data to support BLA filing
− Generate necessary lab-scale development data to support critical ranges
− Generate comparison data of clinical and commercial processes

• Develop commercial scale-up process and move from existing clinical process
− Show comparability between clinical and expected commercial process
− Minimize changes to existing process to shorten timelines and accelerate program
− Utilize knowledge gained through EMU manufacturing for scale-up development

• QbD Risk based approach to parameter studies
− Gain process knowledge and explore processing surface to ensure process parameters are in a stable
zone
− Team not investigating all areas of process, but rather focused on key areas
 Expedites process development and increases team’s efficiency in delivering a commercial process
− Utilizing clinical scale targets
 Only adjusting unit operations necessary to ensure a robust manufacturing process is achieved (i.e.
TFF)

Vaccine Process Flow
Cell Seeding

Formulation (Thaw, Dilute,
Blend)

Cell Passage

Fill Vials

Virus Infection

Stopper/Cap

Virus Harvest

Inspect

Enzyme Treatment

Label

Virus Purification and
Concentration

Package

Freeze at < -60ºC

Freeze at < -60ºC

Ship
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• DS and DP is stored
and kept at < -60C
• Preliminary data
indicates DP stable at
2-8ºC for 3 – 4 weeks
• Next generation
vaccine to explore a
more thermostable
formulation

Vaccine Path to PPQ (Upstream and
Downstream Drug Substance Development)
Process
Development
Kicked Off
[Aug2015]
• Upstream Development •
− MOI
− Plant density
− Day of Infection
− Harvest Time
− PBS Rinse
− Medium Age

Reviewed and
scored prelim
FMEA

Downstream Development •
– Depth Filtration Pmax
Studies
– Enzyme Rxn
• DOE
• Time course studies
– TFF
• DOE
• Impact of Loading

Identified key
experiments
to support
PPQ ranges
Other DS Studies
– Hold time studies
• Stock seed
• HVF
• CH
• RVH
– Investigate various
RB sizes

Impact of MOI and Harvest Time:
Finalized Response Surface Design
Factor

Levels

MOI (1 PFU: viable
cell)

MOIs examined over
100-fold range

Harvest Timing (HPI)

Examined harvesting
over multiple days post
infection

Experiment 1
Conditions 1-30

Replicate experiment
Same design used in both
experiments, replicate to gain
confidence around results

JMP design including
replicates and 6 center
points

30 conditions

Experiment 2
Conditions 1-30

Relative Impact of MOI and Relative
Harvest Time on Potency
Relative Potency Relative
to Commercial Process

110%

100%

90%

80%

Proposed operating space highlighted in red box

•
•

•

Increasing Hours Post Infection

Large operation window for Harvest time and MOI

Data from 3rd & 4th DOE at lower MOI indicates large operating space

Comparison of the Expected Merck
Commercial Process with Clinical Process
• Data presented are for
Harvested Viral Fluids
• Lab-scale results (blue
diamonds) compared to
clinical process (red
circles)
•

Arrows indicate lots
utilized in clinical trials

• Lab-scale and clinical
processes comparable
for potency and harvest
times
•

Development fits well into
operating space

Process Comparability: Clinical /
Emergency Use / Commercial Scale
•
•
•
•

Blue: CMO Clinical
Black: CMO Non-clinical
RED: Merck Lots

Commercial process is
comparable to EMU and
clinical process
•

•
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No significant
differences in final BDS
potencies

Final yields within
clinical experience
range

Expected Process Parameters (Comparison
of Clinical and Commercial Process)
Clinical Process
(CMO)

Commercial Process

Harvesting Time
MOI
Reaction Temperature

No Expected Changes

Reaction Time
Reactor
Mixing Process

GE Wave Bioreactor

200L SU Jacketed
Vessel

Rocking

Bottom Mounted
Magnetic Stirrer

• No significant changes across the process expected
–

Goal is to minimize changes, only modify steps necessary for scale-up
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Vaccine Path to PPQ (DP Development)
• Impact of shear and mixing on final formulated bulk (FFB)
• Short-term stability studies to investigate the impact of normal manufacturing
times and temperatures on drug product potency
− 2-8C
− TOR

• Impact of freezing and thawing
• BDS dilutability studies to target a final DP potency
• Materials of contact experiments and examination of CCI for the final DP
image
− SD and MD vials
− Examination of different formulation vessels (i.e., SS, Glass, SUT)

• Long-term stability studies for DP stability studies
22

DP Results: Impact of Vaccine to Shear
• DP not impacted by shear
stress
•
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DP was exposed to 180
turnovers in an
experimental shear cell

Impact of Freezing Rate of Ebola DP
Stability
• Evaluated impact of
freezing rate on DP
•
•
•

Quick freezing in LN2
blast freezer (15min)
Slow freezing in -70C
freezer (2 & 8hr)
72hr freeze controlled in
Lyophilization cabinet
•

Mimics expected large
lot freezing time

• Method of freezing does
not appear to impact
potency
•

Allows flexibility for
manufacturing and
freeze process

Impact to Thawing Rate on Ebola DP
Potency (10D image)
• Thaw rate impacts DP
potency in 10D image
•

Single Dose Vial study
showed similar trend

• Thawing protocol important
for vaccine field use
•

Thaw at RT to minimize the
thaw time

Ebola DP Freeze / Thaw Stability
• Vaccine appears stable
through 5 Freeze-thaw
cycles
•
•

Flexibility in manufacturing
for packaging and labelling
Vials frozen in -70ºC freezer
and thawed at room
temperature

Dilutability of Ebola BDS to DP Target
Potency
• BDS can be diluted to
specified DP potency
•

Increased confidence in
achieving formulation
and filling targets
•

Examined both clinical
and commercial
processes

Initial Development of Lyophilized
Formulation for Potential Ebola Next Gen
Product

•

All formulations examined achieve acceptable cake appearance with non-optimized
cycle

•

Initial formulation development focused on lyophilization yields and accelerated
stability
•

Utilize accelerated stability to identify lead formulations for long-term stability studies

Tech Transfer Site Readiness Roadmap
Initiation,
Planning,
Capital Project,
Quality System
Assessment,
Analytical TT

Stage
Gate
0

Process & Site
Readiness

Process
Simulations

Stage
Gate 1

Stage
Gate 3

Process
Performance
Qualification Lots
(PPQ)

Engineering Lots

Filing
Preparation,
Comparability
Report &
Pre-launch Audit

Stage
Gate 5

File Submission,
Routine
Manufacturing and
Stability

Stage
Gate 2

Stage
Gate 4

29

Program Challenges
• Three parallel activities within Merck to drive program forward and inability
to sequence
•

Develop Scale-up process for Commercial Manufacturing

•

Manufacture Emergency Use Material to Support a Potential Future Zaire Ebola
Outbreak

•

•
•

Site and Tech Transfer strategy and CapEx project to ready the facility as soon as possible
Process not fully assessed and design space not understood, required development in-lab to
fit to facility and better understand process

•

Ensure doses available prior to licensed product in an emergency / clinical setting

•

Thermostable lyophilized product

Development efforts initiated for next generation vaccine candidate

• Different approaches to risk based decision making
– Team not investigating all areas of process, but rather focused on key areas
•

Expedites process development and increases team’s efficiency in delivering a commercial
process

• Rapidly evolving external environment
•
•

Aug. 2015: Ebola Outbreak in progress; Jan. 2016; WHO declares Ebola outbreak over
Numerous points to interact with during development for both development and funding
•

WHO, GAVI, BARDA, DTRA, DOD, Wellcome Trust, NewLink/BPS, NIH, NIAID
30

Applicability of Strategy Applied for Merck’s
Ebola Vaccine to Other Programs
• Examination of changes in scale and bulk process for later stage
development
•

Changing scale

•

Moving to different platform for production

•

Moving from transient transfectants in early stage development to stable clones

•

Moving from clinical scale to commercial scale

•

RB process to cell stacks or microcarriers for BDS production

• Formulation changes during development
•
•

Biologics utilizing “platform” formulations in early phase programs and later moving
to commercial formulation
Moving from frozen liquid formulations to improved refrigerator stable and
lyophilized formulations as move into Phase II and beyond

• Building strong analytical comparability to minimize clinical
studies

Summary, Conclusions, and Successes
• Merck committed to move the vaccine forward to licensure as quickly as
possible and ensure vaccine availability for at-risk populations in advance of
product licensure
•

Merck has successfully manufactured clinical trial/EMU supplies
•
•

~120K doses available and another ~500K dose equivalents
Filed necessary EUAL with WHO

• Strong preclinical data, including evidence of protection after single dose
•

Positioned the vaccine to be an important vaccine candidate in response to recent Ebola
outbreak

• Merck has shown ability to scale process from clinical to commercial
process
•

Comparability assessment underway between processes

• Initial efforts underway to examine next generation product
•

Thermostable / lyophilized product

• Merck and NewLink working in collaboration with a large number of partners
•

Regulators, Academia, International Health Agencies, NGOs, US Military, and other US
and ex-US government agencies have moved the vaccine forward at an unprecedented
pace

Partnerships and Alliances
Public Health Agency
of Canada (PHAC)

NewLink Genetics (Bio-Protection
Systems Corporation)
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Phase II/III Studies

WHO Clinical Consortium/
Wellcome Trust
̶
̶
̶
̶
̶

•

Switzerland: University Hospitals of Geneva
Germany: University Medical Center
Hamburg/Clinical Trial Center North
Gabon: Centre de Recherches Medicales de
Lambarene/University of Tuebingen
Kenya: Kenya Medical Research Institute
Marburg Laboratory

•
•

•

• CCV – Halifax, Canada
• US Department of Defense
(WRAIR, JVAP, USAMRIID, DTRA)
• NIAID/NIH
• BARDA
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Liberia: Liberia –
NIH Partnership (NIAID)
Sierra Leone: CDC/
Sierra Leone Medical
School, BARDA
Guinea: WHO/Norwegian Institute of Public
Health//MSF/Health Canada
US Department of Defense (WRAIR, JVAP,
USAMRIID, DTRA)
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Thank You!!
Popular Science

V920 Merck’s selection of the NewLink
rVSVΔG-ZEBOV-GP LVV live
attenuated candidate was validated
with extremely positive efficacy results

QUESTIONS?

The V920 internal Merck team is highly functioning, motivated and dedicated. They
have accomplished an extraordinary amount of work with external partners in a
relatively short time frame. “Best team I’ve ever worked with in my career”
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